Jazz Pharmaceuticals
JAZZ
327 hedge funds and large institutions have $6.5B invested in Jazz Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 116 increasing their positions, 133 reducing their positions, and 70 closing their positions.
11% less funds holding
Funds holding: 367 → 327 (-40)
13% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 133
40% less funds holding in top 10
Funds holding in top 10: 15 → 9 (-6)
42% less capital invested
Capital invested by funds: $11.2B → $6.5B (-$4.66B)
43% less call options, than puts
Call options by funds: $51.8M | Put options by funds: $90.7M
53% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$87.8M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$73.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$46.6M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$40.8M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$37.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$76.1M |
| 2 |
Jennison Associates
New York
|
-$74M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$64.7M |
| 4 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$53.5M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$49.8M |
JAZZ Hedge Fund Activity: Q3 2016 in Review
327 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2016, worth a combined $6.5B — down 42% from $11.2B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of JAZZ and 33 opened new positions — a net loss of 37 holders — while 133 trimmed existing stakes and 116 added.
The largest buyer was PFM Health Sciences, adding an estimated $87.8M. The largest seller was Wellington Management Group, cutting an estimated $76.1M.
- 327 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2016, down from 367 in Q2 2016.
- Funds reported $6.5B of Jazz Pharmaceuticals stock for Q3 2016, down 42% quarter-over-quarter.
- 33 funds opened new Jazz Pharmaceuticals positions in Q3 2016 and 70 closed out, a net change of -37 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2016 was PFM Health Sciences, an estimated $87.8M added.
- The largest Jazz Pharmaceuticals seller in Q3 2016 was Wellington Management Group, an estimated $76.1M sold.
Based on aggregated 13F filings for Q3 2016.